GLP-1 for PCOS UK 2026: What the Research Says for Women with PCOS

Polycystic ovary syndrome is not a simple condition, and its treatment has long been unsatisfying. Metformin helps some women with insulin resistance but does little for others. The oral contraceptive pill manages symptoms without addressing the underlying metabolic dysfunction. Lifestyle modification works when it works, but is brutally difficult to sustain when the very hormonal environment of PCOS makes weight gain more likely and weight loss harder.

GLP-1 medications -- specifically semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) -- are now being prescribed for women with PCOS at a significant rate in the UK, despite the absence of a formal PCOS indication. This is not off-the-books prescribing. It reflects a genuine clinical rationale: PCOS and insulin resistance are deeply interlinked, and GLP-1 medications address that link directly.

This article sets out what the research actually shows, what it doesn't yet prove, and what women with PCOS in the UK can realistically expect.

Why PCOS and Insulin Resistance Are Inseparable

Polycystic ovary syndrome is defined clinically by the Rotterdam criteria: two of three features -- irregular or absent periods, biochemical or clinical hyperandrogenism, and polycystic ovarian morphology on ultrasound. But this definition describes symptoms. The metabolic reality is more specific.

Approximately 65-80% of women with PCOS have insulin resistance -- even those who are lean. Hyperinsulinaemia (excess circulating insulin) is not a consequence of PCOS in these women; it is a central driver of it.

Excess insulin:

• Stimulates the ovaries to overproduce androgens (testosterone, androstenedione)
• Reduces sex hormone-binding globulin (SHBG), increasing free testosterone
• Disrupts the LH/FSH ratio, impairing ovulation
• Drives fat storage, particularly visceral and subcutaneous abdominal fat

The result is a self-reinforcing cycle: insulin resistance causes PCOS features, which promote weight gain, which worsens insulin resistance.

Any treatment that improves insulin sensitivity -- meaningfully and durably -- therefore has the potential to address multiple PCOS features simultaneously rather than managing symptoms one at a time.

How GLP-1 Medications Work in This Context

GLP-1 receptor agonists work through several mechanisms that are relevant to PCOS:

Direct insulin secretion improvement: GLP-1 stimulates glucose-dependent insulin secretion from beta cells -- meaning insulin is released when blood glucose is high but not when it is normal. This reduces the fasting hyperinsulinaemia that drives androgen excess.

Insulin sensitisation: Weight loss induced by GLP-1 treatment reduces visceral fat, which is a major source of inflammatory cytokines that impair insulin signalling. As visceral fat decreases, insulin sensitivity improves.

Appetite and calorie regulation: The appetite-suppressing effects of GLP-1 medications make sustained calorie reduction more achievable -- addressing the weight gain cycle that worsens insulin resistance.

Direct ovarian effects: Some early research suggests GLP-1 receptors may be present in ovarian tissue, raising the possibility of direct effects on ovarian function independent of weight loss and insulin improvement. This requires more research before firm conclusions can be drawn.

What the Clinical Evidence Shows

The research base for GLP-1 medications in PCOS is growing, though it is not yet at the scale of the major cardiovascular and metabolic disease trials.

A 2023 meta-analysis examining GLP-1 receptor agonists specifically in women with PCOS found consistent improvements across the following:

• Testosterone and free androgen index -- reduced in the majority of studies
• HOMA-IR (a measure of insulin resistance) -- significantly improved
• Menstrual regularity -- improved in many participants, with some achieving regular cycles after years of amenorrhoea
• BMI and waist circumference -- reduced, with effects comparable to or exceeding metformin in head-to-head studies

The improvements in menstrual regularity are clinically significant. For women who have been told their cycles are unlikely to regulate without the pill, seeing spontaneous cycle restoration on a GLP-1 medication can be striking -- though it should not be interpreted as a guarantee of fertility.

GLP-1 vs Metformin for PCOS: What the Comparisons Show

Metformin is the most widely prescribed medication for insulin resistance in PCOS. It is inexpensive, well-understood, and effective in a subset of patients. However, its effect on weight is modest and its tolerability is variable -- gastrointestinal side effects cause significant numbers of women to discontinue it.

In direct comparisons:

• GLP-1 receptor agonists produce significantly greater weight loss than metformin
• Insulin resistance improvements are comparable or greater with GLP-1 medications
• Androgen reduction is more pronounced with GLP-1 medications in most studies
• Menstrual regularity improvements are more consistent with GLP-1 medications

This does not mean metformin should be discontinued in women already using it. Some evidence suggests combining metformin and a GLP-1 medication produces additive benefits. This is a conversation to have with a prescriber rather than a decision to make independently.

PCOS and Fertility: What GLP-1 Can and Cannot Do

This is where caution is essential.

Improvements in ovulatory function and menstrual regularity during GLP-1 treatment are documented. If cycles normalise and ovulation occurs, fertility theoretically improves. Some women report unintended pregnancies after starting GLP-1 medications having previously been told fertility was significantly impaired.

However:

• GLP-1 medications are not licensed fertility treatments
• Current guidance (NICE and the product information for semaglutide and tirzepatide) recommends stopping these medications at least 2 months before attempting to conceive
• There are insufficient safety data on these medications during pregnancy to recommend continuation
• Women with PCOS who were using a GLP-1 medication and believed themselves to be infertile should not assume they cannot become pregnant

Effective contraception during GLP-1 treatment is essential for women who are not trying to conceive. This needs to be part of the prescribing conversation.

Who Gets GLP-1 Prescribed for PCOS in the UK?

Currently, GLP-1 medications for PCOS in the UK are prescribed almost exclusively through private channels -- either private endocrinologists, private GPs, or online weight management clinics.

NHS prescribing of GLP-1 medications remains tied to:

• Type 2 diabetes (semaglutide via Ozempic, or tirzepatide via Mounjaro in some cases)
• Obesity management with BMI criteria (Wegovy, Mounjaro through specialist weight management services)

PCOS itself is not yet a listed indication for GLP-1 prescribing on the NHS. This may change as evidence accumulates, but as of 2026 it is not yet reflected in NHS prescribing guidance.

For women with PCOS who also meet the BMI criteria for obesity treatment, NHS access may be possible through a weight management pathway. See the NHS GLP-1 eligibility guide for the current criteria.

For those pursuing private prescribing, see the guide to finding the best GLP-1 prescriber in the UK.

Monitoring If You Have PCOS on a GLP-1

If you are taking a GLP-1 medication for PCOS, baseline and follow-up blood tests are important. Consider requesting:

At baseline:

• Total and free testosterone, SHBG, androstenedione
• Fasting insulin and glucose, HOMA-IR if available
• LH, FSH, oestradiol (ideally day 2-4 of cycle, or randomly if cycles are absent)
• Full blood count, thyroid function, vitamin D, ferritin

At 3 and 6 months:

• Repeat androgens and insulin markers
• Weight and waist circumference
• Cycle diary (document regularity, duration, flow)

Rainbow Labs offers a range of at-home blood test kits suitable for monitoring PCOS-related hormonal and metabolic markers.

For a full monitoring framework during GLP-1 treatment, see GLP-1 monitoring protocol.

Managing PCOS Symptoms Alongside GLP-1 Treatment

GLP-1 medications address the metabolic root of PCOS, but other management strategies remain relevant:

Hirsutism (excess hair growth): Androgen-driven hair growth responds slowly to treatment -- typically 6-12 months. Spironolactone, co-cyprindiol, and eflornithine cream are medical options. Physical hair removal methods remain effective alongside medical treatment.

Acne: Androgen-related acne often improves as free testosterone falls, but timing varies. Topical retinoids and antibiotics (prescribed by GP) address active lesions while the hormonal improvement takes effect.

Mood and mental health: PCOS is associated with significantly elevated rates of anxiety and depression. GLP-1 treatment may improve mood through metabolic and neurological mechanisms, but this should not replace appropriate mental health support where needed.

Sleep and fatigue: Sleep-disordered breathing and fatigue are common in PCOS, particularly with insulin resistance. Weight loss on GLP-1 treatment typically improves these substantially.

A Realistic Expectation for GLP-1 Treatment in PCOS

GLP-1 medications are not a cure for PCOS. They address the insulin resistance component powerfully, and improvements in androgen levels, menstrual regularity, and metabolic markers are supported by clinical evidence. They do not repair the underlying genetic and hormonal architecture of the condition.

For many women with PCOS who have struggled with the inadequacy of previous treatment options, GLP-1 medications represent a meaningful step forward. The evidence is not yet at the level required for a formal licensed indication, but it is more substantive than the sparse evidence base for many current PCOS treatments.